Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2024 Feb;99(2):267-270.
doi: 10.1016/j.gie.2023.10.044. Epub 2023 Oct 20.

Novel powered 5.0-mm endoscopic debridement catheter for endoscopic transmural necrosectomy of pancreatic walled-off necrosis: a case series of consecutive patients from a tertiary referral center (with video)

Gitte Aabye Olsen  1 , Palle Nordblad Schmidt  1 , Srdan Novovic  2 , Erik Feldager Hansen  1 , John Gásdal Karstensen  2
Affiliations
Free article
Case Reports

Novel powered 5.0-mm endoscopic debridement catheter for endoscopic transmural necrosectomy of pancreatic walled-off necrosis: a case series of consecutive patients from a tertiary referral center (with video)

Gitte Aabye Olsen et al. Gastrointest Endosc. 2024 Feb.
Free article

Abstract

Background and aims: EUS-guided drainage and, if required, endoscopic necrosectomy (EN) has become the criterion standard for the treatment of pancreatic walled-off necrosis (WON). A dedicated powered endoscopic debridement system, the EndoRotor (Interscope Inc, Northbridge, Mass, USA), has been introduced as an alternative to snare necrosectomy. This study evaluates the novel EndoRotor catheter, NecroMax 6.0 (Interscope Inc, Whitinsville, Mass, USA), for EN in patients with WON.

Methods: This single-center retrospective case series included consecutive patients with WON treated with the NecroMax 6.0 catheter. Safety, ability to perform EN, and clinical resolution were evaluated.

Results: Twenty patients underwent 30 EN procedures with the NecroMax 6.0 catheter. One suspected device-related adverse event was observed (3.3%). In 1 procedure, EN could not be performed because of excessive bending of the endoscope. Eighteen patients (90.0%) achieved clinical resolution.

Conclusions: EN with the NecroMax 6.0 catheter was technically feasible in 96.7% of patients with a low rate of adverse events.

PubMed Disclaimer

Conflict of interest statement

Disclosure The following authors disclosed financial relationships: P. N. Schmidt: Consultant for Ambu and Boston Scientific; speaker for Norgine. J. G. Karstensen: Consultant for Ambu, Boston Scientific, and SNIPR BIOME; speaker for Norgine. All other authors disclosed no financial relationships. Research support for this study (J. G. K. and G. A. O.) was provided in part by The Novo Nordisk Foundation (NNF21OC0072262).

LinkOut - more resources